Cargando…
Transcriptomic Analysis Reveals the Protection of Astragaloside IV against Diabetic Nephropathy by Modulating Inflammation
BACKGROUND: Diabetic nephropathy (DN) is one of the leading causes of end-stage kidney disease. Recently, there is no specific drug available to block the kidney damage. Astragaloside IV (AS-IV) is a major active component of Astragalus membranaceus (Fisch) Bge and has been demonstrated to benefit t...
Autores principales: | Zhang, Yudi, Tao, Chunhe, Xuan, Chen, Jiang, Junyan, Cao, Wenfu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7443226/ https://www.ncbi.nlm.nih.gov/pubmed/32855769 http://dx.doi.org/10.1155/2020/9542165 |
Ejemplares similares
-
Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network
por: Liu, Xinhui, et al.
Publicado: (2017) -
Astragaloside IV protects against diabetic nephropathy via activating eNOS in streptozotocin diabetes-induced rats
por: Fan, Yuyan, et al.
Publicado: (2019) -
Review on the protective mechanism of astragaloside IV against cardiovascular diseases
por: Yang, Chunkun, et al.
Publicado: (2023) -
Astragaloside IV protects RGC-5 cells against oxidative stress
por: Hao, Ming, et al.
Publicado: (2018) -
The Astragaloside IV Derivative LS-102 Ameliorates Obesity-Related Nephropathy
por: Li, Ziyu, et al.
Publicado: (2022)